U
ATRC icon

UBS’s AtriCure ATRC Stock Holding History

UBS’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$4K Sell
250
-6,525
-96% -$104K ﹤0.01% 9588
2014
Q2 		$125K Buy
6,775
+6,525
+2,610% +$109K ﹤0.01% 5676
2014
Q1 		$5K Buy
250
+152
+155% +$3.12K ﹤0.01% 9497
2013
Q4 		$2K Sell
98
-476
-83% -$6.92K ﹤0.01% 10009
2013
Q3 		$6K Buy
+574
New +$5.66K ﹤0.01% 9228

Other funds holding ATRC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return

UBS's ATRC Position: Q3 2014 in Review

UBS reduced its AtriCure (ATRC) stake by 96% in Q3 2014, selling an estimated $104K and leaving 250 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #9588.

UBS first reported a position in ATRC in Q3 2013 and has held it in 5 quarters since. The position peaked at $125K in Q2 2014. 112 funds tracked by Wall St. Rank hold ATRC as of Q3 2014.

  • UBS held 250 shares of AtriCure worth $4K as of Q3 2014.
  • UBS sold 6,525 AtriCure shares in Q3 2014, an estimated $104K.
  • AtriCure made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9588 holding.
  • UBS first reported a position in AtriCure in Q3 2013 and has held it in 5 quarters since.
  • UBS's AtriCure position peaked at $125K in Q2 2014.
  • 112 funds tracked by Wall St. Rank held AtriCure as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.